|
Protocol ID |
Official Title |
PI Name |
Lead CRC |
Disease Site |
Phase |
| A011106
ClinicalTrials.gov #
|
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study | S. Ghamande | Kelly Adams | Breast |
III |
| A011202
ClinicalTrials.gov #
|
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy | S. Ghamande | Inquiries | Breast | III |
| NRG-BR003
ClinicalTrials.gov #
|
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | S. Ghamande |
Kelly Adams | Breast | III |
| NSABP-B55
ClinicalTrials.gov #
|
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy | S. Ghamande |
Inquiries | Breast | III |
| S1207
ClinicalTrials.gov #
|
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer | S. Ghamande |
Kelly Adams | Breast | III |
|
S1416 ClinicalTrials.gov # NCT02595905
|
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer | S. Ghamande | Kelly Adams | Breast | II |
|
S1418 ClinicalTrials.gov# NCT02954874 |
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy | S. Ghamande | Kelly Adams | Breast | III |
